Previous close | 0.3620 |
Open | 0.3850 |
Bid | 0.4010 x 3000 |
Ask | 0.4080 x 29200 |
Day's range | 0.3600 - 0.3994 |
52-week range | 0.3400 - 7.0700 |
Volume | |
Avg. volume | 7,996,945 |
Market cap | 93.411M |
Beta (5Y monthly) | 1.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.1110 |
Earnings date | 08 Aug 2022 - 12 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.33 |
Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.
Endo International (NASDAQ: ENDP), a specialty pharmaceutical company, saw its shares fall 69% on Wednesday. It was already a bad day for many companies with the Dow and the S&P 500 down more than 3% and the NASDAQ falling more than 4%. The biggest reason for Endo's massive drop came when The Wall Street Journal reported the company was negotiating to restructure its more-than $8 billion in debt with its lenders and senior bondholders.
Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.